AAS
TEVA icon

Ameritas Advisory Services’s Teva Pharmaceuticals TEVA Stock Holding History

Ameritas Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-330
Closed -$2.9K – 2326
2023
Q1 		$2.9K Buy
+330
New +$3.26K ﹤0.01% 2306

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Advisory Services's TEVA Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 330 shares — an estimated $2.9K sold.

Ameritas Advisory Services first reported a position in TEVA in Q1 2023 and held it in 1 quarter. The position peaked at $2.9K in Q1 2023. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Ameritas Advisory Services reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ameritas Advisory Services sold 330 Teva Pharmaceuticals shares in Q2 2023, an estimated $2.9K.
  • Ameritas Advisory Services first reported a position in Teva Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Ameritas Advisory Services's Teva Pharmaceuticals position peaked at $2.9K in Q1 2023.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.